The safety and efficacy of aprepitant in combination with other antiemetic agents for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric patients-Reference-Cited by-同舟云学术

The safety and efficacy of aprepitant in combination with other antiemetic agents for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric patients

Published:2016-04-18 Issue:3 Volume:1 Page:189-195
ISSN:2380-9000
Container-title:Expert Review of Quality of Life in Cancer Care
language:en
Short-container-title:Expert Review of Quality of Life in Cancer Care

Author:

Batra Atul,Bakhshi Sameer

Publisher

Informa UK Limited

Link

http://www.tandfonline.com/doi/pdf/10.1080/23809000.2016.1174069

Reference35 articles.

1. Increasing diversity in pediatric hematology/oncology

2. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines

3. Prospective Validation of Risk Prediction Indexes for Acute and Delayed Chemotherapy-Induced Nausea and Vomiting

4. Chemotherapy-Induced Nausea and Vomiting

5. The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost‐effectiveness analysis of aprepitant‐based anti‐emetic regimen for children receiving highly emetogenic chemotherapy: Individual patient data analysis of a randomized trial;Pediatric Blood & Cancer;2022-06-02

2. Antiemetic Regimen with Olanzapine in Pediatric Patients Receiving Highly Emetogenic Chemotherapy;Indian Journal of Medical and Paediatric Oncology;2021-08

3. Electrochemically Simulated Oxidative Metabolization Pattern of Neurokinin-1 Antagonist Aprepitant;Journal of The Electrochemical Society;2020-05-20